Suit-Fong Chan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Suit-Fong Chan has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- He Cheng
MiRXES Lab, Singapore
2 shared publications - Kai-Wen Huang
Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
2 shared publications Chun-Jung Chang
Hepatitis Research Center, Graduate Institute of Microbiology, Department of Surgery, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
1 shared publicationHao-Tien Wang
1 shared publicationHao-Wei Cheng
Graduate Institute of Microbiology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
1 shared publicationHiroshi Matsuoka
Division of Bioresource Research and Development, Kobe University Graduate School of Medicine, Japan
1 shared publication
Latest Publications
- Open Access
- 17 May 2026
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 48, 101251
Development and validation of a plasma miRNA-CEA biomarker panel for early detection of lung cancer
- 17 May 2026
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 48, 101251
Open AccessDevelopment and validation of a plasma miRNA-CEA biomarker panel for early detection of lung cancer
- Open Access
- 6 April 2023
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 25 (7) , 438-453
Preanalytic Methodological Considerations and Sample Quality Control of Circulating miRNAs
- 6 April 2023
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 25 (7) , 438-453
Open AccessPreanalytic Methodological Considerations and Sample Quality Control of Circulating miRNAs
- 1 July 2012
- Published by Elsevier in Cancer Letters
- Vol. 320 (1) , 23-30
Anti-angiogenic therapy renders large tumors vulnerable to immunotherapy via reducing immunosuppression in the tumor microenvironment
- 1 July 2012
- Published by Elsevier in Cancer Letters
- Vol. 320 (1) , 23-30
Anti-angiogenic therapy renders large tumors vulnerable to immunotherapy via reducing immunosuppression in the tumor microenvironment
- Open Access
- 26 February 2007
- Published by Wolters Kluwer Health in Hepatology
- Vol. 45 (3) , 746-754
Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors
Immunotherapy is often effective only for small tumor burdens and, in many cases, is restricted to subcutaneous tumors. Here, we investigated the antitumor effects of combination therapy with GM-CSF and IL-12 on orthotopic liver tumors with intermediate or large tumor volumes, or on chemically-induced multifocal liver tumors in animals. Adenoviruses encoding GM-CSF or IL-12 were injected intratumorally to animals bearing transplanted tumors, or injected via intrahepatic artery in animals with primary multifocal liver tumors induced by diethylnitrosamine. Our results demonstrated that IL-12, but not GM-CSF, monotherapy displayed significant therapeutic effects, whereas combination therapy with both cytokines displayed synergistic antitumor effects not only on transplanted tumor models with intermediate or large tumor loads, but also on carcinogen-induced multifocal liver tumors. Effector cell analyses, revealed by in vivo cell subset depletion, flow cytometry analysis, and immunohistochemical staining of tumor infiltrates, indicated that NK cells were the prominent antitumor effectors for the IL-12–mediated antitumor activity, whereas CD8+ T cells, NKT cells, and macrophages were more important than NK cells in the combination therapy–mediated antitumor effects. Both IL-12 monotherapy and combination therapy could induce various types of effectors and high levels of IFN-γ; however, the latter induced much higher levels than the former, which may explain why combination therapy is superior to IL-12 monotherapy. Conclusion: Combination therapy with GM-CSF and IL-12 represents a promising immunotherapy strategy for treating orthotopic, widespread liver tumors. (Hepatology 2007;45:746–754.)
- 26 February 2007
- Published by Wolters Kluwer Health in Hepatology
- Vol. 45 (3) , 746-754
Open AccessCombined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors
Immunotherapy is often effective only for small tumor burdens and, in many cases, is restricted to subcutaneous tumors. Here, we investigated the antitumor effects of combination therapy with GM-CSF and IL-12 on orthotopic liver tumors with intermediate or large tumor volumes, or on chemically-induced multifocal liver tumors in animals. Adenoviruses encoding GM-CSF or IL-12 were injected intratumorally to animals bearing transplanted tumors, or injected via intrahepatic artery in animals with primary multifocal liver tumors induced by diethylnitrosamine. Our results demonstrated that IL-12, but not GM-CSF, monotherapy displayed significant therapeutic effects, whereas combination therapy with both cytokines displayed synergistic antitumor effects not only on transplanted tumor models with intermediate or large tumor loads, but also on carcinogen-induced multifocal liver tumors. Effector cell analyses, revealed by in vivo cell subset depletion, flow cytometry analysis, and immunohistochemical staining of tumor infiltrates, indicated that NK cells were the prominent antitumor effectors for the IL-12–mediated antitumor activity, whereas CD8+ T cells, NKT cells, and macrophages were more important than NK cells in the combination therapy–mediated antitumor effects. Both IL-12 monotherapy and combination therapy could induce various types of effectors and high levels of IFN-γ; however, the latter induced much higher levels than the former, which may explain why combination therapy is superior to IL-12 monotherapy. Conclusion: Combination therapy with GM-CSF and IL-12 represents a promising immunotherapy strategy for treating orthotopic, widespread liver tumors. (Hepatology 2007;45:746–754.)